



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
2100 RENAISSANCE BLVD.
KING OF PRUSSIA, PA 19406-2713

May 9, 2019

Ulrich Roth, Ph.D., Site Head Development US
& Head of Development NCE
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
P. O. Box 368
Ridgefield, CT 06877-0368

SUBJECT: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., LICENSE
AMENDMENT, MAIL CONTROL NO. 612057

Dear Dr. Roth:

This refers to your license amendment request dated April 24, 2019. Please find enclosed Amendment No. 28 authorizing a new Radiation Safety Officer and notifying us of a change in the Radiation Safety Committee Chair.

An environmental assessment for this action was not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please contact me at (610) 337-5040 or by electronic mail to Elizabeth.Ullrich@nrc.gov so that appropriate corrections or answers can be provided.

You will be periodically inspected by the NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action(s) against you. This could include issuance of a Notice of Violation, or Imposition of a Civil Penalty, or an Order Suspending, Modifying or Revoking Your License as specified in the NRC Enforcement Policy. The NRC Enforcement Policy is available at:
<http://www.nrc.gov/reading-rm/doc-collections/enforcement/>.

An electronic version of the NRC's regulations is available on the NRC Web Site at: www.nrc.gov. Additional information regarding use of radioactive materials may be obtained on the NRC Web Site at: <http://www.nrc.gov/materials/miau/mat-toolkits.html>. This site also provides the link to the toolbox for updated information on the revised regulations for naturally-occurring and accelerator-produced radioactive materials (NARM).

The NRC's Safety Culture Policy Statement became effective in June 2011. While a policy statement and not a regulation, it sets forth the agency's *expectations* for individuals and organizations to establish and maintain a positive safety culture. You can access the policy statement and supporting material that may benefit your organization on NRC's safety culture Web Site at: <http://www.nrc.gov/about-nrc/safety-culture.html>. We strongly encourage you to review this material and adapt it to your particular needs in order to develop and maintain a positive safety culture as you engage in NRC-regulated activities.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web Site at: <http://www.nrc.gov/reading-rm/adams.html>.

Thank you for your cooperation.

Sincerely,



Betsy Ullrich, Senior Health Physicist
Commercial, Industrial, R&D
and Academic Branch
Division of Nuclear Materials Safety
Region I

Docket No. 030-17101
License No. 06-19183-01
Mail Control No. 612057

Enclosure:
Amendment No. 28

cc: Drané O'Brien, Radiation Safety Officer

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., LICENSE AMENDMENT, MAIL CONTROL NO. 612057 DATED MAY 9, 2019

DOCUMENT NAME: [Document1- UPDATE FIELD]
SUNSI Review Complete: [INSERT SUNSI REVIEWER NAME]

After declaring this document "An Official Agency Record" it will be released to the Public.
To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	RI:DNMS	N					
NAME	G. J. [Signature]						
DATE	5/9/19						

OFFICIAL RECORD COPY